DBV TECHNOLOGIE/S (NASDAQ:DBVT) – Stock analysts at Jefferies Financial Group issued their FY2023 earnings per share (EPS) estimates for DBV TECHNOLOGIE/S in a research note issued to investors on Thursday, August 1st. Jefferies Financial Group analyst E. Yang anticipates that the company will post earnings of $1.55 per share for the year.
A number of other analysts have also issued reports on the company. BidaskClub lowered DBV TECHNOLOGIE/S from a “hold” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research lowered DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a research report on Tuesday. ValuEngine raised DBV TECHNOLOGIE/S from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Goldman Sachs Group assumed coverage on DBV TECHNOLOGIE/S in a research report on Monday, June 17th. They issued a “buy” rating and a $14.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $14.81.
Hedge funds and other institutional investors have recently made changes to their positions in the business. DekaBank Deutsche Girozentrale raised its position in shares of DBV TECHNOLOGIE/S by 1,600.0% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 40,800 shares of the company’s stock worth $325,000 after buying an additional 38,400 shares in the last quarter. Aperio Group LLC bought a new stake in shares of DBV TECHNOLOGIE/S in the 2nd quarter worth approximately $152,000. LeJeune Puetz Investment Counsel LLC bought a new stake in shares of DBV TECHNOLOGIE/S in the 2nd quarter worth approximately $108,000. FNY Investment Advisers LLC bought a new stake in shares of DBV TECHNOLOGIE/S in the 2nd quarter worth approximately $102,000. Finally, Pictet Asset Management Ltd. raised its holdings in shares of DBV TECHNOLOGIE/S by 47.5% in the 1st quarter. Pictet Asset Management Ltd. now owns 124,746 shares of the company’s stock worth $1,881,000 after purchasing an additional 40,171 shares in the last quarter. 46.30% of the stock is currently owned by institutional investors.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Article: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.